Machine-Learning-Assisted Analysis of Patient Clinical Biomarkers to Improve Ovarian Cancer Diagnosis

Machine-Learning-Assisted Analysis of Patient Clinical Biomarkers to Improve Ovarian Cancer Diagnosis

The unavailability of accurate and reliable methods for early ovarian cancer detection represents a major gap in ovarian cancer diagnosis and management. The emergence and recent integration of machine learning with cancer diagnostic techniques, particularly biomarker-based blood tests, have the pot...

Deskribapen osoa

Gorde:

Xehetasun bibliografikoak
Egile nagusia:	Célia Sahli (17289760) (author)
Beste egile batzuk:	Tiffany Thanhtruc Pham (21633026) (author), Kenry (8678085) (author)
Argitaratua:	2025
Gaiak:	Genetics Cancer Statistics Space Science Biological Sciences not elsewhere classified Mathematical Sciences not elsewhere classified Chemical Sciences not elsewhere classified Information Systems not elsewhere classified cancer discriminatory power cancer diagnostic techniques ovarian cancer screening ovarian cancer diagnosis reliable diagnostic results relevant quantitative approaches based blood tests patient clinical biomarkers patient menopausal status improve patient outcomes benign ovarian tumors machine learning algorithms ovarian tumors menopausal status benign tumors patient populations statistical approaches reliable methods clinical features 47 blood systematic consideration recent integration premenopausal patients postmenopausal patients particularly biomarker obtained features necessary prior major gap machine learning feature selection critical feature assisted analysis 300 patients
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak

Data Sheet 1_Identification of the key immune gene NR3C1 as a diagnostic biomarker in differentiating ovarian borderline tumors from benign tumors.zip
nork: Shiying Chen (2563039)
Argitaratua: (2025)

Data Sheet 1_TCR and BCR repertoire analysis reveals distinct signatures between benign and malignant ovarian tumors.pdf
nork: Zhonghuang Wang (11228215)
Argitaratua: (2025)

Supplementary Figure S1 from Surgical and Blood-Based Minimal Residual Disease in Patients with Ovarian Cancer after First-line Therapy: Clinical Outcomes and Translational Opportunities
nork: Anne Knisely (22348576)
Argitaratua: (2025)

Supplementary Figure S2 from Surgical and Blood-Based Minimal Residual Disease in Patients with Ovarian Cancer after First-line Therapy: Clinical Outcomes and Translational Opportunities
nork: Anne Knisely (22348576)
Argitaratua: (2025)

Supplementary Figure S3 from Surgical and Blood-Based Minimal Residual Disease in Patients with Ovarian Cancer after First-line Therapy: Clinical Outcomes and Translational Opportunities
nork: Anne Knisely (22348576)
Argitaratua: (2025)

Supplementary Figure S4 from Surgical and Blood-Based Minimal Residual Disease in Patients with Ovarian Cancer after First-line Therapy: Clinical Outcomes and Translational Opportunities
nork: Anne Knisely (22348576)
Argitaratua: (2025)

Supplementary Table S1 from Surgical and Blood-Based Minimal Residual Disease in Patients with Ovarian Cancer after First-line Therapy: Clinical Outcomes and Translational Opportunities
nork: Anne Knisely (22348576)
Argitaratua: (2025)

Supplementary Table S2 from Surgical and Blood-Based Minimal Residual Disease in Patients with Ovarian Cancer after First-line Therapy: Clinical Outcomes and Translational Opportunities
nork: Anne Knisely (22348576)
Argitaratua: (2025)

Supplementary Table S3 from Surgical and Blood-Based Minimal Residual Disease in Patients with Ovarian Cancer after First-line Therapy: Clinical Outcomes and Translational Opportunities
nork: Anne Knisely (22348576)
Argitaratua: (2025)

Supplementary Table S4 from Surgical and Blood-Based Minimal Residual Disease in Patients with Ovarian Cancer after First-line Therapy: Clinical Outcomes and Translational Opportunities
nork: Anne Knisely (22348576)
Argitaratua: (2025)

Supplementary Table S5 from Surgical and Blood-Based Minimal Residual Disease in Patients with Ovarian Cancer after First-line Therapy: Clinical Outcomes and Translational Opportunities
nork: Anne Knisely (22348576)
Argitaratua: (2025)

Table 1_Treatment provision and management for the menopause: a multinational survey study.docx
nork: Nayra A. Martin-Key (12856953)
Argitaratua: (2025)

Supplementary Tables and Figures 1 from Effectiveness of PARP Inhibitor Maintenance Therapy in Ovarian Cancer by BRCA1/2 and a Scar-Based HRD Signature in Real-World Practice
nork: Debra L. Richardson (15086145)
Argitaratua: (2025)

Figure 1 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
nork: Nicola S. Meagher (15048462)
Argitaratua: (2025)

Figure 2 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
nork: Nicola S. Meagher (15048462)
Argitaratua: (2025)

Figure 3 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
nork: Nicola S. Meagher (15048462)
Argitaratua: (2025)

Supplementary Tables S1-S11 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
nork: Nicola S. Meagher (15048462)
Argitaratua: (2025)

Table 1 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
nork: Nicola S. Meagher (15048462)
Argitaratua: (2025)

Table 2 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
nork: Nicola S. Meagher (15048462)
Argitaratua: (2025)

Table 3 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
nork: Nicola S. Meagher (15048462)
Argitaratua: (2025)

Figure 1 from Decoding the Genomic and Functional Landscape of Emerging Subtypes in Ovarian Cancer
nork: Giulia Micoli (22547985)
Argitaratua: (2025)

Figure 2 from Decoding the Genomic and Functional Landscape of Emerging Subtypes in Ovarian Cancer
nork: Giulia Micoli (22547985)
Argitaratua: (2025)

Figure 3 from Decoding the Genomic and Functional Landscape of Emerging Subtypes in Ovarian Cancer
nork: Giulia Micoli (22547985)
Argitaratua: (2025)

Figure 4 from Decoding the Genomic and Functional Landscape of Emerging Subtypes in Ovarian Cancer
nork: Giulia Micoli (22547985)
Argitaratua: (2025)

Figure 5 from Decoding the Genomic and Functional Landscape of Emerging Subtypes in Ovarian Cancer
nork: Giulia Micoli (22547985)
Argitaratua: (2025)

Supplementary Table S1 from Decoding the Genomic and Functional Landscape of Emerging Subtypes in Ovarian Cancer
nork: Giulia Micoli (22547985)
Argitaratua: (2025)

Table 1 from Decoding the Genomic and Functional Landscape of Emerging Subtypes in Ovarian Cancer
nork: Giulia Micoli (22547985)
Argitaratua: (2025)

Table 2 from Decoding the Genomic and Functional Landscape of Emerging Subtypes in Ovarian Cancer
nork: Giulia Micoli (22547985)
Argitaratua: (2025)

Supplemental Table S3 from Spatial Transcriptomic Analysis of Ovarian Cancer Precursors Reveals Reactivation of IGFBP2 during Pathogenesis
nork: Yeh Wang (14964041)
Argitaratua: (2025)

Supplemental Table S4 from Spatial Transcriptomic Analysis of Ovarian Cancer Precursors Reveals Reactivation of IGFBP2 during Pathogenesis
nork: Yeh Wang (14964041)
Argitaratua: (2025)

Table 1_Proteomic alterations in ovarian cancer—Predicting residual disease status using artificial intelligence and SHAP-based biomarker interpretation.docx
nork: Seyma Yasar (18715204)
Argitaratua: (2025)

Supplementary Data 1 from Unraveling the Tumor Microenvironment and PD-L1 Expression across Tissue Types in High-Grade Serous Ovarian Cancer in the NeoPembrOV/GINECO Phase II Randomized Trial
nork: Laetitia Collet (21903637)
Argitaratua: (2025)

Supplementary Data 2 from Unraveling the Tumor Microenvironment and PD-L1 Expression across Tissue Types in High-Grade Serous Ovarian Cancer in the NeoPembrOV/GINECO Phase II Randomized Trial
nork: Laetitia Collet (21903637)
Argitaratua: (2025)

Supplementary Data 3 from Unraveling the Tumor Microenvironment and PD-L1 Expression across Tissue Types in High-Grade Serous Ovarian Cancer in the NeoPembrOV/GINECO Phase II Randomized Trial
nork: Laetitia Collet (21903637)
Argitaratua: (2025)

Figure 1 from Defining the Ovarian Cancer Precancerous Landscape through Modeling Fallopian Tube Epithelium Reprogramming Driven by Extracellular Vesicles
nork: Jared Sipes (21980223)
Argitaratua: (2025)

Figure 2 from Defining the Ovarian Cancer Precancerous Landscape through Modeling Fallopian Tube Epithelium Reprogramming Driven by Extracellular Vesicles
nork: Jared Sipes (21980223)
Argitaratua: (2025)

Figure 3 from Defining the Ovarian Cancer Precancerous Landscape through Modeling Fallopian Tube Epithelium Reprogramming Driven by Extracellular Vesicles
nork: Jared Sipes (21980223)
Argitaratua: (2025)

Figure 4 from Defining the Ovarian Cancer Precancerous Landscape through Modeling Fallopian Tube Epithelium Reprogramming Driven by Extracellular Vesicles
nork: Jared Sipes (21980223)
Argitaratua: (2025)

Figure 5 from Defining the Ovarian Cancer Precancerous Landscape through Modeling Fallopian Tube Epithelium Reprogramming Driven by Extracellular Vesicles
nork: Jared Sipes (21980223)
Argitaratua: (2025)

Figure 6 from Defining the Ovarian Cancer Precancerous Landscape through Modeling Fallopian Tube Epithelium Reprogramming Driven by Extracellular Vesicles
nork: Jared Sipes (21980223)
Argitaratua: (2025)